Adipotide vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- Estimated 2-4 hours
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Subcutaneous, Intravenous (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- Not established for humans; primate studies used 0.1-1 mg/kg
- 10 mg per day
- Frequency
- Daily for 4 weeks (research protocol)
- Daily for 10–30 days
- Key Benefits
- Targeted reduction of white adipose tissue
- Promotes fat vasculature apoptosis without systemic toxicity
- Demonstrated significant fat loss in primate studies
- Potential for visceral and subcutaneous fat reduction
- Novel non-hormonal mechanism distinct from GLP-1 agonists
- Explored for obesity and metabolic syndrome
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Renal toxicity observed in primate studies (transient, dose-dependent)
- Dehydration and electrolyte imbalances in research
- Weight regain upon cessation
- Limited human data; side effect profile largely from animal studies
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —